Document Classification

Section Type: RESULTS

Text: Compared with baseline values, rosiglitazone adversely affected levels of lymphotoxin receptor (1. 7 vs 2. 4 ng/mL, P =. 002), peptidoglycan recognition protein 1 (29. 0 vs 30. 1 ng/mL, P =. 01), and chemokine ligand 23 (0. 76 vs 0. 84 ng/mL, P =. 02) and favorably affected levels of sRAGE (inversely associated with atherosclerosis, 1. 1 vs 1. 4 ng/mL, P =. 003) and hs-CRP (0. 42 vs 0. 31 ng/mL, P =. 02) ; no changes were observed with rosiglitazone in the other biomarkers.